top of page

Industry opinion

Dec 4, 2025

A discussion with Stanley Kim and Rob Robertson

Two journeys. One shared vision.

As CRScube and Mednet begin our new chapter together, we spoke with Stanley Kim and Rob Robertson about the clinical industry, the companies they built, and the experiences that shaped their leadership. Their reflections reveal two distinct paths that ultimately align around shared values: adaptability, collaboration, and a commitment to delivering meaningful impact for customers.

Culture and how we work

Although both companies were built in different environments, there is a strong sense of culture and belonging at their core.

For Stanley, CRScube is driven by “persistence and swift action,” an approach where teams address customer challenges decisively and fully. As Stanley says himself, we “don’t stop halfway.” 

Rob described Mednet’s culture as deeply collaborative, explaining that success comes from collective effort: “I don’t believe one or two people are the key to a company’s success, it is the collaboration of the entire team.” 

Together, these perspectives reinforce a culture that listens carefully, works across boundaries, and moves forward with purpose.

What they value most in their teams

Both leaders recognise that a strong team has more impact than individuals working independently. They built CRScube and Mednet into successful businesses by bringing in the right people, in the right role. In true leaders, they steered their company in the right direction, leaning on their teams as a strength to move forward, consistently.

Stanley emphasised CRScube’s integrated way of working, noting that “we don’t have silos… We move in the same direction with one shared goal: delivering true customer satisfaction.” 

For Rob, the defining strength of his team is their commitment: “Their mindset is to put the customer first and do everything possible to make them happy.” 

Both leaders highlight the same core: people who act with dedication and unity. This cultural alignment is a key foundation for integrating both businesses successfully.

The role of mid-sized companies

In an industry where large vendors are the default – even if not the best – option, one may wonder how CRScube and Mednet have become such strong businesses, supplying to a large number of clients.

Considering the position CRScube holds in our industry, Stanley highlighted how the shifting landscape of clinical research creates opportunities. He noted that “clinical trials today are far more diverse and variable than in the past, and large vendors often cannot adapt quickly enough to those changes. Companies like ours fill that gap… we help new therapies reach patients faster, and more safely.” 

Rob shared a complementary view shaped by Mednet’s evolution. For him, mid-sized companies offer sponsors an essential alternative, one defined by responsiveness and close relationships. As he put it, such organisations “provide all companies with an alternative to the industry leaders… while being more responsive, focused, flexible, agile, and cost-effective.” 

Though expressed differently, both leaders see mid-sized organisations as vital partners in advancing clinical research with speed and intention. CRScube and Mednet’s clients recognise the benefit of being able to adapt faster, especially in an industry often criticised for its slow innovation.

Formative early moments

CRScube and Mednet were not built in a day. They are the result of hard work over many years, and key events that shaped both companies into what they are today.

When reflecting on early milestones, Stanley spoke about a defining moment in CRScube’s expansion: “I often think back to the day I sent a bold, almost reckless email to the Chairman of one of our key clients… It was the moment that shaped my belief that nothing happens unless you take the first step.” 

Rob recalled one of Mednet’s first major client win. Competing against a much larger vendor at a time when the company had only five employees, the team worked intensely to earn not just the first study but the next. He explained, “We never considered ourselves successful with a customer until they gave us their second study.” 

Both experiences – though separated by geography and circumstance – illustrate leadership shaped by determination and a willingness to take meaningful risks.

Looking ahead, together

While CRScube and Mednet will continue serving their existing clients in the same way as usual, both leaders reflect on what a future together looks like.

Stanley sees the combined organisation as uniquely positioned for global growth, sharing that “CRScube’s strength in Asia and Mednet’s strength in North America together give us a path to true global expansion.” 

Rob expressed confidence in what can be achieved with the combined assets of both teams, stating that we have “the teams, experience, talent, collaboration, financial resources, cost efficiencies, products and service to make this happen.” 

Their aligned outlook signals a clear and ambitious direction: one company, united by shared purpose, moving toward global excellence.

placeholder_white_300x300.jpg

Share via

See CRScube in action

Explore how our platform will elevate your team and clinical trial management.

crscube_in_action_ca.avif

Get insights straight to your inbox

img_001.avif

Explore our knowledge base

Stay in-the-know with regular updates and industry opinions from our expert team.

Featured resources

icon_01.png

A discussion with Stanley Kim and Rob Robertson

Although both CRScube and Mednet were built in different environments, there is a strong sense of culture and belonging at their core.

icon_01.png

Beyond the data: Human stories from clinical trials in Ukraine

From halting patient recruitment and struggling with the shipment of investigational medicines, to relocating vulnerable oncology patients across borders, Anna paints a vivid picture of resilience and resourcefulness under pressure.

icon_01.png

Why Mednet. Why Now.

CRScube and Mednet are a natural fit. We are both innovators in eClinical technology. We both operate on a SaaS model, serve the same customers, and believe in transforming clinical trials.

bottom of page